HBM Healthcare Reports Profit Despite Share Price Decline

HBM Healthcare Investments AG announced a profit of CHF 66 million for the first nine months of the 2024/2025 financial year, ending December 31, 2024. This success is primarily attributed to private companies, which generated CHF 100 million through asset sales, including the IPOs of Upstream Bio and Sai Life Sciences. However, the share price dropped by 5.2%, widening the NAV discount to nearly 30%.

Public companies in their portfolio saw a minor decline in value. Some companies, like Argenx and Travere Therapeutics, recorded share price increases, while others, such as Y-mAbs Therapeutics, faced significant decreases.

HBM's diversified portfolio, with 31% private and 49% public companies, remains balanced. Looking forward, the company plans to enhance shareholder value through strategic investments and expects improved market sentiment in 2025.